ASP3026

DRUG2 trials

Sponsors

Astellas Pharma Inc

Conditions

Advanced MalignanciesB-Cell LymphomaPositive for Anaplastic Lymphoma KinasePositive for Proto-Oncogene Tyrosine-Protein Kinase ROSSolid Tumor

Phase 1

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

CompletedNCT01284192

Astellas Pharma IncAdvanced Malignancies, B-Cell Lymphoma, Positive for Anaplastic Lymphoma Kinase +2

Start: 2010-12-31End: 2016-03-31Updated: 2016-06-28

Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors

CompletedNCT01401504

Astellas Pharma IncSolid Tumor

Start: 2011-05-31End: 2014-01-31Updated: 2014-06-11

Related Papers

Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study

Drugs in R&D2020-12-174 citations

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.

2016-03-1020 citations

Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.

Journal of Clinical Oncology2014-05-2022 citations